文献速递肿瘤 PET/CT

靶向整合素αvβ6的胱氨酸结肽18F-FP-R01-MG-F2在胰腺癌患者中的先导期PET/CT研究

Pilot-phase PET/CT study targeting integrin αvβ6 in pancreatic cancer patients using the cystine-knot peptide-based 18F-FP-R01-MG-F2.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-11-03

这项先导期研究前瞻性纳入15例组织学确诊的胰腺癌患者,在2017年3月至2021年2月间行18F-FP-R01-MG-F2(一种靶向整合素αvβ6的胱氨酸结肽)PET/CT,评估安全性、生物分布、剂量学和病灶摄取。结果显示该药物安全,有效剂量为2.538×10⁻² mSv/MBq,可检测全部已知胰腺肿瘤,但未检出3例淋巴结转移患者中2例的短径小于1 cm的胰周小淋巴结,作者认为该显像可行但需更大样本研究明确其作用。

要点

  • 15例胰腺癌患者注射18F-FP-R01-MG-F2后未见符合不良事件或严重不良事件的生命体征或实验室值显著变化。
  • 注射后1小时高摄取区包括垂体、胃、十二指肠、肾和膀胱(平均SUVmean 9.7-14.5),正常胰腺为中等摄取(平均SUVmean 4.5)。
  • 该PET/CT检出全部15例患者的已知胰腺肿瘤及肺、肝、腹膜远处转移,但未检出3例淋巴结转移患者中2例的短径<1 cm胰周淋巴结。

核心结论

  • 18F-FP-R01-MG-F2是一种安全的PET放射性药物,有效剂量与其他诊断药物相当;用其PET评估原发胰腺癌和远处转移是可行的,但需要更大规模研究来确定该方法的作用。

研究设计与样本

  • 前瞻性先导期研究,纳入15例(6男、9女)组织学确诊的胰腺癌患者,于2017年3月至2021年2月行18F-FP-R01-MG-F2 PET/CT(ClinicalTrials.gov标识NCT02683824)。

主要发现

  • 注射后未见符合不良事件或严重不良事件的生命体征或实验室值显著变化。
  • 注射后1小时高摄取区包括垂体、胃、十二指肠、肾和膀胱(平均SUVmean 9.7-14.5),正常胰腺为中等摄取(平均SUVmean 4.5),肺和肝为轻度摄取(平均SUVmean<1.0)。
  • 有效剂量计算为2.538×10⁻² mSv/MBq。
  • Knottin PET/CT检出15例患者全部已知胰腺肿瘤;在3例手术证实淋巴结转移的患者中,2例短径小于1 cm的胰周小淋巴结未被检出。
  • Knottin PET/CT检出肺(n=5)、肝(n=4)和腹膜(n=2)远处转移,经活检和/或增强CT确认。

临床怎么用

  • 作者认为,用18F-FP-R01-MG-F2 PET评估原发胰腺癌和远处转移是可行的,但需要更大规模研究来确定该方法的作用。

局限性

  • 作者指出需要更大规模研究来确定该方法的作用。
  • 在3例手术证实淋巴结转移的患者中,2例短径小于1 cm的胰周小淋巴结未被Knottin PET/CT检出。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A novel cystine-knot peptide-based PET radiopharmaceutical, 18F-FP-R01-MG-F2 (knottin), was developed to selectively bind to human integrin αvβ6 which is overexpressed in pancreatic cancer. The purpose of this study is to evaluate the safety, biodistribution, dosimetry, and lesion uptake of 18F-FP-R01-MG-F2 in patients with pancreatic cancer. METHODS: Fifteen patients (6 men, 9 women) with histologically confirmed pancreatic cancer were prospectively enrolled and underwent knottin PET/CT between March 2017 and February 2021 (ClinicalTrials.gov Identifier NCT02683824). Vital signs and laboratory results were collected before and after the imaging scans. Maximum standardized uptake values (SUVmax) and mean SUV (SUVmean) were measured in 24 normal tissues and pancreatic cancer lesions for each patient. From the biodistribution data, the organ doses and whole-body effective dose were calculated using OLINDA/EXM software. RESULTS: There were no significant changes in vital signs or laboratory values that qualified as adverse events or serious adverse events. At 1 h post-injection, areas of high 18F-FP-R01-MG-F2 uptake included the pituitary gland, stomach, duodenum, kidneys, and bladder (average SUVmean: 9.7-14.5). Intermediate uptake was found in the normal pancreas (average SUVmean: 4.5). Mild uptake was found in the lungs and liver (average SUVmean < 1.0). The effective dose was calculated to be 2.538 × 10-2 mSv/MBq. Knottin PET/CT detected all known pancreatic tumors in the 15 patients, although it did not detect small peri-pancreatic lymph nodes of less than 1 cm in short diameter in two of three patients who had lymph node metastases at surgery. Knottin PET/CT detected distant metastases in the lungs (n = 5), liver (n = 4), and peritoneum (n = 2), confirmed by biopsy and/or contrast-enhanced CT. CONCLUSION: 18F-FP-R01-MG-F2 is a safe PET radiopharmaceutical with an effective dose comparable to other diagnostic agents. Evaluation of the primary pancreatic cancer and distant metastases with 18F-FP-R01-MG-F2 PET is feasible, but larger studies are required to define the role of this approach. TRIAL REGISTRATION: NCT02683824.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Nakamoto R, Ferri V, Duan H, et al. Pilot-phase PET/CT study targeting integrin αvβ6 in pancreatic cancer patients using the cystine-knot peptide-based 18F-FP-R01-MG-F2. Eur J Nucl Med Mol Imaging. 2021. PMID: 34729628. doi:10.1007/s00259-021-05595-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。